Author + information
- Keri L. Mondaa,b,
- John Acquavellaa,b,
- David Smitha,b,
- Patrick Stewarta,b,
- Thomas Maddoxa,b,
- Steven Bradleya,b and
- Gregory Hessa,b
Background: Patients undergoing percutaneous coronary intervention (PCI) remain at high risk of a subsequent CV event. While the indication for the PCI is an important predictor of subsequent cardiac morbidity and mortality, much remains to be learned about other predictors. To that end, in these initial analyses, we describe by PCI indication the comorbidity burden and lipid-lowering treatment use in a large sample of patients with linked pharmacy and medical claims data assembled for outcomes research.
Methods: We identified 587,367 adult patients from the NCDR CathPCI Registry who underwent PCI between 1/1/2012 and 3/31/2014. Patients also had at least one pharmacy and medical claim, and could not have undergone a PCI, in the 365 days prior to their index PCI.
Results: Patients in our sample were mostly male (66.1%) and 52.5% were between 65-84 years. PCI indications were STEMI (14.4%), NSTEMI (24.4%), unstable angina (UA, 41.8%), or elective (19.4%). Patients tended to be overweight and many had a history of CV comorbidities. Statin and ezetimibe use in the year prior to the index PCI varied by indication between 27-42% (table).
Conclusions: We observed a high level of comorbid conditions and other risk factors across PCI indications; nonetheless, at the time of event, between 49-70% of these patients were not receiving evidence-based lipid-lowering therapies. Follow-on analyses will further characterize this observation as well as evaluate predictors of subsequent CV risk.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Current Issues in Cardiovascular Epidemiology, Disparities, and Safety
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1148-070
- 2017 American College of Cardiology Foundation